-
1 Comment
CardieX Limited is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.9.
CardieX Limited's total revenue rose by 16.1% to $3M since the same quarter in the previous year.
Its net income has dropped by 5.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.0% to $-475K since the same quarter in the previous year.
Based on the above factors, CardieX Limited gets an overall score of 4/5.
Industry | Medical Devices |
---|---|
Sector | Healthcare |
ISIN | AU0000015729 |
CurrencyCode | AUD |
Exchange | AU |
PE Ratio | 0.0 |
---|---|
Dividend Yield | 0.0% |
Target Price | None |
Beta | 1.73 |
Market Cap | 36M |
CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company undertakes contracts with pharmaceutical companies for the use of SphygmoCor XCEL devices; provides lab and data management services for clinical trials comprising end-to-end service that delivers clean datasets to study sponsors. It also develops home vascular health solutions, remote patient monitoring, decentralized clinical trials and solutions wearables, and medical health apps under the CONNEQT name, as well as CONNEQT Pulse device, a home-based heart health vital signs monitoring system, that measures central blood pressure, arterial waveforms, and various other proprietary arterial health parameters through its SphygmoCor technology. The company serves hospitals, clinics, research institutions and pharmaceutical companies. It has strategic collaboration agreement with LifeQ, Inc for wearable devices. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CDX.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024